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Abstract
Background: The alpha1A-adrenergic receptor (α1A-AR) regulates the cardiac and peripheral
vascular system through sympathetic activation. Due to its important role in the regulation of
vascular tone and blood pressure, we aimed to investigate the association between the Arg347Cys
polymorphism in the α1A-AR gene and blood pressure phenotypes, in a large sample of Brazilians
from an urban population.
Methods: A total of 1568 individuals were randomly selected from the general population of the
Vitória City metropolitan area. Genetic analysis of the Arg347Cys polymorphism was conducted
by polymerase chain reaction/restriction fragment length polymorphism. We have compared
cardiovascular risk variables and genotypes using ANOVA, and Chi-square test for univariate
comparisons and logistic regression for multivariate comparisons.
Results: Association analysis indicated a significant difference between genotype groups with
respect to diastolic blood pressure (p = 0.04), but not systolic blood pressure (p = 0.12). In
addition, presence of the Cys/Cys genotype was marginally associated with hypertension in our
population (p = 0.06). Significant interaction effects were observed between the studied genetic
variant, age and physical activity. Presence of the Cys/Cys genotype was associated with
hypertension only in individuals with regular physical activity (odds ratio = 1.86; p = 0.03) or
younger than 45 years (odds ratio = 1.27; p = 0.04).
Conclusion: Physical activity and age may potentially play a role by disclosing the effects of the
Cys allele on blood pressure. According to our data it is possible that the Arg347Cys
polymorphism can be used as a biomarker to disease risk in a selected group of individuals.
Background
Increased blood pressure constitutes a major risk factor for
cardiovascular diseases, including kidney and cerebrovas-
cular diseases[1,2]. Although the underlying molecular
mechanisms remain largely elusive, it is well known that
blood pressure is tightly regulated through a net of com-
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plex interrelationships between several physiological sys-
tems[3]. In addition, several well-designed studies have
provided strong evidence that blood pressure variability is
largely determined by genetic factors[4,5].
The alpha1A-adrenergic receptor (α1A-AR) regulates the
cardiac and peripheral vascular system through sympa-
thetic activation. Because of this characteristic, the α1A-AR
is considered an important participant in blood pressure
homeostasis[6]. The human α1A-AR gene (ADRA1A),
located on chromosome 8q21[7], have an Arg347Cys pol-
ymorphism (rs1048101, previously described as
Arg492Cys) located in the region coding for the carboxyl
terminus of the receptor[8]. The arginine (Arg) → cysteine
(Cys) substitution at the amino acid position 347 can
confer a palmitoylation site and may modulate the cellu-
lar localization of the protein[8]. This variant has no
apparent effect on the functional properties in vitro[8],
and an initial report found no association between this
polymorphism and hypertension[9]. However, recent
studies showed that the Cys allele was associated with rel-
atively lower hypertension prevalence in a Chinese popu-
lation[10], and its carriers had a significantly greater
blood pressure decrease with short-term Ibersatan treat-
ment in a sample of Chinese hypertensive individu-
als[11]. These results suggested that genetic variations in
ADRA1A could modulate cardiac or vascular sympathetic
tone and might contribute to the pathogenesis of hyper-
tension and cardiovascular disease.
In this report, we aimed to investigate the association
between the Arg347Cys polymorphism, environmental
risk factors and blood pressure phenotypes, in a large sam-
ple of Brazilians randomly selected from an admixed
urban population.
Methods
Study Population
A cross-sectional study of risk factors for cardiovascular
diseases was performed in the urban population of
Vitória, Brazil, using the WHO-MONICA project guide-
lines[12]. A sample of 2044 individuals (from an eligible
population of 137330) of either gender, 25 to 64 years of
age, was chosen according to the nearest birthday after a
random selection of domiciles. The recruitment process
occurred from April, 1999 to November, 2000.
Participants (n = 1573) attended the clinic visit and the
physical examination emphasized measurement of
height, weight, and blood pressure. Major cardiovascular
risk factors, such as, obesity phenotypes, ethnicity, smok-
ing status, amount of physical activity, hypertension and
metabolic syndrome, were also evaluated. Laboratorial
analyses were conduced to evaluate blood glucose, total-
cholesterol, lipoprotein fraction, and triglycerides.
This study was approved by Ethics Committee for
Research on Human Subject of the Universidade Federal
do Espírito Santo, and all subjects gave written informed
consent to participate.
Anthropologic Investigation and Biochemical 
Measurements
Presence of traditional cardiovascular risk factors was
determined using the criteria standardized by The Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pres-
sure[13]. Weight and height were measured according to
a standard protocol, with participants wearing light cloth-
ing and no shoes. Height was measured in centimeters
and weight in kilograms using a calibrated balance. Body
mass index (BMI) (weight in Kg/height in meters2) was
calculated and overweight or obesity defined as BMI ≥ 25
or 30 Kg/m2, respectively. All participants were also sub-
mitted to a racial classification according to a validated
questionnaire for the Brazilian population[14,15]. Sub-
jects were classified as Caucasian or African-descent
according to a set of phenotypic characteristics (skin
color, hair texture, shape of the nose, aspect of the lip, and
jaw position). On the basis of these characteristics, mulat-
tos are considered racially mixed subjects. Individuals
who had ever smoked more than five cigarettes per day for
the least a year were classified as smokers, and sedentary
lifestyle was defined as exercise less than one hour, three
times a week.
According to the Third Report of the National Cholesterol
Education Program criteria[16], metabolic syndrome was
defined when any two or more of following risk determi-
nant were present: (1) abdominal obesity (waist circum-
ference ≥ 102 cm in men, and ≥ 88 cm in women); (2)
fasting glucose ≥ 100 mg/dL, (3) hypertension (systolic
blood pressure ≥ 130 mmHg and/or diastolic blood pres-
sure ≥ 85 mmHg in at least two measurement or the cur-
rent use of anti-hypertensive medication) and (4) total-
cholesterol ≥ 200 mg/dL, triglycerides ≥ 150 mg/dL, LDL-
cholesterol ≥ 130 mg/dL and HDL-cholesterol ≤ 40 mg/
dL. Blood glucose, total cholesterol, lipoprotein fractions,
and triglycerides were assayed by standard techniques in
12-hour fasting blood samples.
Determination of blood pressure phenotypes
Blood pressure was measured using a standard mercury
sphygmomanometer on the left arm after 5 minutes rest,
in the sitting position. Systolic and diastolic blood pres-
sures were calculated from three readings, with a minimal
interval of 5 minutes and the average value was used in
the analysis. Hypertension was defined as mean systolic
blood pressure (SBP) of ≥ 130 mmHg and/or diastolic
blood pressure (DBP) of ≥ 85 mmHg or the current use of
anti-hypertensive medication[16]. This definition wasBMC Cardiovascular Disorders 2008, 8:40 http://www.biomedcentral.com/1471-2261/8/40
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used to standardize the hypertension classification in
both hypertensive individual and metabolic syndrome
subjects.
Genotyping Protocols
Genomic DNA was extracted from leukocytes in samples
of whole blood, following a standard salting-out tech-
nique[17]. Genotypes were detected by polymerase chain
reaction (PCR) followed by restriction fragment length
polymorphism (RFLP) analysis as previously
described[18]. Quality control for these assays was
assessed by randomly selecting 60 samples to be re-geno-
typed by two independent technicians.
Statistical Analysis
Comparisons of continuous variables were performed by
Student unpaired t-test, while χ2 tests were used for cate-
gorical variables. Allele and genotype frequencies among
the study participants were calculated using the StatView
for Windows statistical program (version 5.0). The good-
ness of fit for normal distribution was evaluated using the
Kolmogorov-Smirnov test. Hardy-Weinberg equilibrium
for the distribution of the genotypes was estimated by the
χ2 test using the StatView program. The effects of ethnicity
on blood pressure status and genotype frequencies were
analyzed by χ2 tests.
Unpaired t test and ANOVA were used to investigate the
association between genotype and the different pheno-
types studied. The association between Arg347Cys poly-
morphism and blood pressure phenotypes was assessed
by analysis of odds ratio (OR), respective 95% confidence
intervals (CI) and two-tailed p value (Epi-Info statistical
program, version 3.2.2). Genetic models of action of the
studied variants were constructed by combining geno-
types (i.e., recessive model = homozygous for the Cys
allele).
Association between a particularly chosen genetic model,
common risk factors (gender, age, obesity, ethnicity,
smoking status, sedentary lifestyle, total-cholesterol, lipo-
protein fractions, triglycerides, blood glucose, metabolic
syndrome) and blood pressure phenotype was examined
with simple and multiple logistic regressions. These anal-
yses were conduced using the SPSS program (version
12.0).
Quantitative variables were expressed as the mean ±
standard deviation, and p values < 0.05 on a two-tailed
test were considered statistically significant.
Results
Demographic and Genetic Structure Data
Table 1 summarizes the demographic data stratified per
Arg347Cys genotypes. In all ethnic groups, allele and gen-
Table 1: Baseline characteristics and clinical data for conventional risk factors per genotype.
Parameters Arg/Arg Arg/Cys Cys/Cys p
N° individuals 287 813 473
Anthropologic characteristics
Gender, Male, % 44.8 43.7 46.8 0.262
Age, years 45.0 ± 11.5 44.9 ± 10.6 44.4 ± 10.8 0.721
BMI, kg/m2 26.4 ± 5.0 26.1 ± 5.0 26.5 ± 4.6 0.327
Waist circunference, cm Male 90.5 ± 12.6 88.5 ± 11.2 89.7 ± 10.7 0.212
Female 83.3 ± 12.8 83.6 ± 12.5 84.9 ± 13.2 0.257
Obesity, % 55.1 53.4 60.3 0.058
Ethnicity, % Caucasian 44.0 35.0 31.0
Mulatto 48.1 55.0 56.2 0.000
Negroid 7.9 10.0 12.8
Smoking, % 23.7 22.5 20.3 0.737
Sedentary Lifestyle, % 70.8 76.0 73.5 0.221
Blood pressure
SBP, mmHg 125.8 ± 20.4 127.9 ± 22.0 129.2 ± 22.5 0.122
DBP, mmHg 82.6 ± 13.2 84.1 ± 14.1 85.2 ± 14.2 0.044
Pulse Pressure, mmHg 43.2 ± 14.0 43.8 ± 13.3 43.9 ± 14.3 0.748
Hypertension, % 40.1 41.6 45.5 0.263
Blood biochemistry
Total Cholesterol, mg/dL 215.7 ± 45.9 214.5 ± 45.0 213.6 ± 53.4 0.838
LDL-Cholesterol, mg/dL 142.9 ± 39.9 142.5 ± 39.0 141.4 ± 41.1 0.839
HDL-Cholesterol, mg/dL 44.7 ± 13.0 46.0 ± 12.6 44.7 ± 11.5 0.109
Triglicerides, mg/dL 150.2 ± 162.6 133.0 ± 102.0 138.2 ± 143.2 0.149
Glucose, mg/dL 105.8 ± 31.1 104.6 ± 32.0 105.1 ± 32.8 0.867
Glucose intolerance, % 20.2 21.4 22.9 0.851
Metabolic syndrome, % 28.9 23.3 27.0 0.112BMC Cardiovascular Disorders 2008, 8:40 http://www.biomedcentral.com/1471-2261/8/40
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otype frequencies were in accordance with the Hardy-
Weinberg equilibrium (p > 0.05). Genotypes were differ-
ently distributed regarding ethnicity (p < 0.001). This dif-
ference was due to a higher frequency of the Cys allele in
African-descendent individuals as compared to Cauca-
sian-descendent ones.
Association Between Blood Pressure Phenotypes and 
ADRA1A Genotypes
Association analysis indicated a significant difference
between genotype groups with respect to diastolic blood
pressure and a tendency towards increased systolic blood
pressure associated with the presence of the Cys allele
using an additive mode of action (Table 1).
Considering a recessive mode of action for the Cys allele
(Cys/Cys vs. Arg/Arg + Arg/Cys individuals), presence of
the Cys/Cys genotype was marginally associated with
hypertension in our population (OR = 1.334; CI = 0.995–
1.532; p = 0.056). After adjustment for gender, age, and
ethnicity, presence of the risk allele in homozygosis was
not significant (OR = 1.21; CI = 0.96–1.53; p = 0.11).
Exploring potential interaction effects between the
Arg347Cys polymorphism and other determinants of
blood pressure, we have interestingly observed a context-
dependent effect of the polymorphism regarding physical
activity (Figure 1). In this scenario, the Arg347Cys poly-
morphism is associated with hypertension only in indi-
viduals with regular physical activity. In this sub-
population of fitted individuals, we observed that the
hypertensive status was associated with Cys/Cys genotype
(OR = 1.86, CI = 1.06–3.26, p = 0.03; adjusted for gender,
obesity, ethnicity, smoking status, dyslipidemia, diabetes
and metabolic syndrome gender). We did not find evi-
dence for an interaction effect between the studied genetic
variant and obesity (p = 0.23), smoking status (p = 0.66),
total-cholesterol (p = 0.46), LDL-cholesterol (p = 0.74),
HDL-cholesterol (p = 0.71), triglycerides (p = 0.84), glu-
cose intolerance (p = 0.84) or metabolic syndrome (p =
0.67).
Another way of testing this potentially relevant interaction
effect is to study the differential effect on hypertensive sta-
tus modulated by the Arg347Cys variant comparing pop-
ulations with different ages. Here, we have hypothesized
that individuals of younger age (and conceivably fitter)
may show a different effect of the Cys/Cys genotype when
compared to the same genotype effect in individuals from
a higher age group. In Figure 2, we show the different
prevalence of hypertension according with the Arg347Cys
genotypes in different sub-groups defined by the median
age of our population, 45 years. Interestingly, in individ-
uals with less than 45 years there is a clear association
involving the Cys/Cys genotype hypertension phenotype
(OR = 1.27; CI = 1.01–1.59; p = 0.04). On the contrary,
Hypertension prevalence according to physical activity and Arg347Cys genotypes Figure 1
Hypertension prevalence according to physical activity and Arg347Cys genotypes.
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despite a higher prevalence of hypertension in the older
individuals sample, there is no clear association between
the Cys/Cys genotype and hypertension (p = 0.46).
Discussion
The data presented in this study provide evidence for a
discrete association between Arg347Cys polymorphism
and blood pressure related phenotypes in the general pop-
ulation studied. Nevertheless, a stronger association
between the Cys allele and hypertension was clearly
observed in the subpopulations of fitted and young indi-
viduals. These findings suggest that the effect of this allele
in blood pressure regulation is only evident when taking
into account physical fitness. Physical activity, potentially,
may play a role by disclosing the effects of the Cys allele
on blood pressure, consequently uncovering the associa-
tion between them.
Alpha1-adrenergic receptors (α1A-AR,  α1B-AR e α1C-AR)
are G protein-coupled transmembrane receptors that
mediate actions in the sympathetic nervous system
through the binding of catecholamines[19]. Among three
subtypes of human α1-ARs, the α1A-AR is the predominant
subtype in vascular smooth muscle. Genetically engi-
neered knock-out mice for the α1A-AR have demonstrated
that this subtype has a vasopressor role in resistance arter-
ies and is required to maintain normal arterial blood pres-
sure[20]. Although functional differences between the
Arg347 and Cys347 receptors have yet to be identified, the
potential relevance of α1A-AR genetic variation to multiple
pathophysiological conditions have been examined with
negative results. However, most studies were carried in
small sample sizes and underpowered to explore small
effect-sizes and gene-environment interac-
tions[8,9,11,18,21].
Not in contrast with these findings, a recent study by Jiang
and co-authors [11] showed that α1A-AR Cys allele carriers
had a significantly greater blood pressure response to
short-term Irbesartan treatment. Snapir and co-authors
[22] observed that young healthy subjects homozygous
for the Cys allele had a tendency to increased systolic
blood pressure and longer electrocardiogram RP interval
before and during the adrenaline infusion. Moreover,
Iacovello and co-workers [23] described a strong associa-
tion between the Cys allele and autonomic control of
heart rate in healthy individuals. The observed association
between the Cys allele and hypertension in a subpopula-
tion of young individuals or with regular physical activity
in the present study may be in part responsible for the
physiological implications of this polymorphism. Cer-
tainly, in the current research design, we could not
exclude the possibility that the Arg347Cys polymorphism
or other functional genetic variant in linkage disequilib-
rium with it may have a potential clinical implication for
α1A-AR-mediated physiology in relation to blood pressure
Hypertension prevalence according to age and Arg347Cys genotypes Figure 2
Hypertension prevalence according to age and Arg347Cys genotypes.
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modulation. In this case, haplotype analysis may provide
further information on this issue.
The alpha1A-adrenergic receptor mediates vasoconstric-
tion and plays an important role in the regulation of vas-
cular tone. It is well documented that sympathetic nerve
stimulation produces substantial vasoconstriction in skel-
etal muscle via α1- and α2-adrenergic receptors[24]. Sim-
ilarly, both receptors contribute to sympathetic
vasoconstriction in skeletal muscle at rest and during exer-
cise[25]. In addition, the mechanisms mediating post-
exercise hypotension may indeed require the participa-
tion of the alpha-adrenergic receptor system[26].
Although the study of physiological control systems
known to contribute to the regulation of blood pressure
during exercise had shed light on the complex interrela-
tions between hypertension and physical activity, the
molecular basis of the relationship between these two
conditions remain poorly understood. It is interesting to
note that we were able to observe an association between
the Cys/Cys genotype and hypertension only in individu-
als with regular physical activity. This fact may relates to
the important role of alpha-adrenergic receptors in mod-
ulating blood pressure homeostasis during and after exer-
cise[25].
Our study has potential limitations: (1) perhaps a case-
control study design may be more informative to evaluate
the hypertension susceptibility than the present cross-sec-
tional study; (2) blood pressure measurements were taken
in only one visit instead of the more accepted procedure
of three different medical visits; (3) our analysis has
shown the existence of significant population structure
and the statistical power associated to stratified ethnic
subgroup analysis was significantly reduced in compari-
son with that associated to the whole population analysis;
(4) we used the III Report of the National Cholesterol
Education Program criteria to classify hypertension status.
This procedure was applied in order to standardize the
hypertension classification in both hypertensive individ-
ual and metabolic syndrome subjects. In this context, the
present observations should be considered cautiously in
relation to the pathology of hypertension and cardiovas-
cular disease; (5) the functional role of Arg347Cys poly-
morphism is still unknown, but epidemiological studies
have been suggesting that this molecular variant may be
associated with blood pressure controlling mechanisms
and hypertension status; (6) we have only genotyped the
Arg347Cys SNP in the ADRA1A (the most common non-
synonymous naturally occurring SNP in the α1A-AR) and
other(s) SNP(s) may, in fact, be more relevant for the
reported association[19]. Nevertheless, at least for the
studied population, we were able to show that the studied
genetic marker has predictive power to stratify individuals
according to hypertension risk. It remains to be tested
whether different markers in the same gene will also be
predictive of hypertension risk.
Conclusion
Present data suggested that, although ADRA1A Cys allele
may have a discrete effect in individuals from the general
population, it might become a relevant marker of the
hypertension risk in individuals younger than 45-years.
Moreover, these findings provide further insights for the
understanding of the complex modulation of blood pres-
sure by exercise activity. Future work should be carried-
out in order to understand the context-dependent effect of
the Arg347Cys variant regarding physical activity and to
shed light on the potential role of ADRA1A genotype for
predicting exercise-induced hypotension.
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